NewCelX is developing NCEL-101, an enriched stem cell-derived islet cell therapy designed to restore functional insulin production through scalable, off-the-shelf cell replacement.
Published
Signal category
Research & Knowledge
Quote
“At NewCelX (Nasdaq: NCEL), this is exactly where our focus is with NCEL-101 — our enriched stem cell-derived islet cell therapy designed to restore functional insulin production through scalable, off-the-shelf cell replacement.”
— NewCelX team
Company
NewCelX
Biotechnology company advancing transformative therapies for neurodegenerative and metabolic diseases
- Industry
- Biotechnology Research
- Location
- Kloten, CH
- Company size
- 30 employees
NewCelX Ltd. (Nasdaq: NCEL) is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company’s integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. NewCelX is headquartered in Zurich, Switzerland, with research and development operations in Ness Ziona, Israel.
Founded 2009